Compare III & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | CNTN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | 1500 | 3 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.8M | 184.2M |
| IPO Year | 2006 | 2022 |
| Metric | III | CNTN |
|---|---|---|
| Price | $4.34 | $3.55 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | 201.1K | ★ 605.4K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | ★ 216.67 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $192,745,000.00 | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | $22.84 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $3.57 | $2.98 |
| 52 Week High | $6.45 | $5.27 |
| Indicator | III | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 48.25 |
| Support Level | $4.12 | $3.07 |
| Resistance Level | $5.14 | $5.27 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 92.87 | 69.23 |
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.